Citigroup’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-425
| Closed | -$472 | – | 5129 |
|
|
2022
Q4 | $472 | Sell |
425
-977
| -70% | -$1.09K | ﹤0.01% | 4719 |
|
|
2022
Q3 | $3K | Sell |
1,402
-54,791
| -98% | -$117K | ﹤0.01% | 4646 |
|
|
2022
Q2 | $170K | Buy |
56,193
+53,671
| +2,128% | +$162K | ﹤0.01% | 3280 |
|
|
2022
Q1 | $17K | Sell |
2,522
-7,350
| -74% | -$49.5K | ﹤0.01% | 4509 |
|
|
2021
Q4 | $82K | Buy |
9,872
+3,503
| +55% | +$29.1K | ﹤0.01% | 4065 |
|
|
2021
Q3 | $47K | Buy |
6,369
+1,696
| +36% | +$12.5K | ﹤0.01% | 4024 |
|
|
2021
Q2 | $32K | Buy |
4,673
+2,663
| +132% | +$18.2K | ﹤0.01% | 4379 |
|
|
2021
Q1 | $21K | Sell |
2,010
-2,424
| -55% | -$25.3K | ﹤0.01% | 4577 |
|
|
2020
Q4 | $31K | Buy |
4,434
+3,605
| +435% | +$25.2K | ﹤0.01% | 4392 |
|
|
2020
Q3 | $7K | Sell |
829
-2,184
| -72% | -$18.4K | ﹤0.01% | 4524 |
|
|
2020
Q2 | $21K | Sell |
3,013
-2,834
| -48% | -$19.8K | ﹤0.01% | 4221 |
|
|
2020
Q1 | $28K | Buy |
5,847
+825
| +16% | +$3.95K | ﹤0.01% | 4191 |
|
|
2019
Q4 | $44K | Buy |
5,022
+286
| +6% | +$2.51K | ﹤0.01% | 4052 |
|
|
2019
Q3 | $16K | Buy |
4,736
+604
| +15% | +$2.04K | ﹤0.01% | 4390 |
|
|
2019
Q2 | $21K | Sell |
4,132
-134
| -3% | -$681 | ﹤0.01% | 4565 |
|
|
2019
Q1 | $26K | Sell |
4,266
-1,794
| -30% | -$10.9K | ﹤0.01% | 4411 |
|
|
2018
Q4 | $20K | Buy |
6,060
+2,597
| +75% | +$8.57K | ﹤0.01% | 4425 |
|
|
2018
Q3 | $22K | Sell |
3,463
-13,405
| -79% | -$85.2K | ﹤0.01% | 4485 |
|
|
2018
Q2 | $129K | Buy |
16,868
+1,244
| +8% | +$9.51K | ﹤0.01% | 3251 |
|
|
2018
Q1 | $350K | Sell |
15,624
-51
| -0.3% | -$1.14K | ﹤0.01% | 2538 |
|
|
2017
Q4 | $200K | Buy |
15,675
+13,665
| +680% | +$174K | ﹤0.01% | 2969 |
|
|
2017
Q3 | $31K | Sell |
2,010
-72
| -3% | -$1.11K | ﹤0.01% | 3857 |
|
|
2017
Q2 | $29K | Sell |
2,082
-4,282
| -67% | -$59.6K | ﹤0.01% | 3813 |
|
|
2017
Q1 | $140K | Buy |
+6,364
| New | +$140K | ﹤0.01% | 3163 |
|